TEVA logo

TEVA

Teva Pharmaceutical Industries LimitedNYSEHealthcare
$30.08-0.56%ClosedMarket Cap: $35.03B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

24.86

PEG

0.13

P/B

4.33

P/S

2.00

EV/EBITDA

15.66

DCF Value

$26.59

FCF Yield

4.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

51.8%

Operating Margin

18.2%

Net Margin

8.2%

ROE

20.1%

ROA

6.8%

ROIC

10.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$4.71B$480.0M$0.41
FY 2025$17.26B$1.41B$1.20
Q3 2025$4.48B$433.0M$0.37
Q2 2025$4.18B$282.0M$0.24

Analyst Ratings

View All
Piper SandlerOverweight
2026-03-04
Truist SecuritiesBuy
2026-02-18
Goldman SachsBuy
2026-02-09
BarclaysOverweight
2026-01-30
ScotiabankSector Outperform
2026-01-29

Trading Activity

Insider Trades

View All
Sabag Markofficer: See "Remarks"
SellThu Mar 19
Sabag Markofficer: See "Remarks"
SellMon Mar 09
Kalif Eliyahu Sharonofficer: EVP, Chief Financial Officer
SellMon Mar 09
Weiss Amirofficer: Chief Accounting Officer
SellMon Mar 09
Francis Richard Dofficer: President and CEO
SellMon Mar 09

Company Info

Sector

Healthcare

Industry

Country

IL

Exchange

NYSE

Beta

0.76

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Peers